THE ARISING · Longevity & Healthspan
VITAL found fewer heart attacks with fish oil, but its main outcome did not improve
November 17, 2026 · Longevity & Healthspan · By The Arising Longevity & Healthspan Desk
A new review by the VITAL investigators revisits a result that is easy to oversimplify. In their original randomized trial, a daily fish-oil capsule did not significantly reduce the combined outcome of heart attack, stroke or cardiovascular death. Heart attacks considered separately were less common, but that was a secondary result.
The trial assigned 25,871 U.S. adults to fish oil or placebo and followed them for a median of 5.3 years. There were 304 major cardiovascular events in the fish-oil group and 333 in the placebo group; the hazard ratio was 0.92 (95% confidence interval 0.80–1.06). For heart attacks alone, the counts were 145 and 200, respectively, with a hazard ratio of 0.72 (0.59–0.90).
Those two findings can coexist. The heart-attack result concerns one outcome among several, and it does not overturn the uncertainty around the trial's primary cardiovascular outcome. The 2026 overview draws on the same VITAL trial, not a new randomized replication. It does not establish a general reason to start taking fish oil.